Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values
Pouneh S. Mofrad,Melissa J. Contos,Mahmadul Haque,Carol Sargeant,Robert A. Fisher,Velimir A. Luketic,Richard K. Sterling,Mitchell L. Shiffman,Richard T. Stravitz,Arun J. Sanyal +9 more
Reads0
Chats0
TLDR
The entire histologic spectrum of NAFLD can be seen in individuals with normal ALT values, and the Histologic spectrum in these individuals is not significantly different from those with elevated ALT levels, which means a lownormal ALT value does not guarantee freedom from underlying steatohepatitis with advanced fibrosis.About:
This article is published in Hepatology.The article was published on 2003-06-01 and is currently open access. It has received 1086 citations till now. The article focuses on the topics: Nonalcoholic fatty liver disease & Fatty liver.read more
Citations
More filters
Journal ArticleDOI
Nonalcoholic fatty liver disease: From steatosis to cirrhosis
TL;DR: The present “gold standard” management of NASH is modest weight reduction, particularly correction of central obesity achieved by combining dietary measures with increased physical activity, which improves insulin resistance and reverses steatosis, hepatocellular injury, inflammation, and fibrosis.
Journal ArticleDOI
Nonalcoholic Fatty Liver Disease: A Systematic Review
TL;DR: How to identify patients with nonalcoholic fatty liver disease at greatest risk of non Alcoholic steatohepatitis and cirrhosis is illustrated and the role and limitations of current diagnostics and liver biopsy are discussed to provide an outline for the management of patients across the spectrum of non alcoholic fatty Liver disease.
Journal ArticleDOI
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt,Hannes Hagström,Patrik Nasr,Mats Fredrikson,Per Stål,Stergios Kechagias,Rolf Hultcrantz +6 more
TL;DR: NAFLD patients have increased risk of death, with a high risk ofdeath from cardiovascular disease and liver‐related disease, and the NAS was not able to predict overall mortality, whereas fibrosis stage predicted both overall and disease‐specific mortality.
Journal ArticleDOI
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Renata Belfort,Stephen A. Harrison,Kenneth A. Brown,Celia Darland,Joan Finch,Jean Hardies,Bogdan Balas,Amalia Gastaldelli,Amalia Gastaldelli,Fermin O. Tio,Joseph P. Pulcini,Rachele Berria,Jennie Z. Ma,Sunil Dwivedi,Russell Havranek,Chris Fincke,Ralph A. DeFronzo,George A. Bannayan,Steven Schenker,Kenneth Cusi +19 more
TL;DR: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis and larger controlled trials of longer duration are warranted to assess the long-term clinical benefit.
Journal ArticleDOI
Nonalcoholic fatty liver disease
TL;DR: The etiology, pathogenesis and diagnosis of nonalcoholic fatty liver disease as well as approaches to its management are discussed in this paper, where the authors discuss the etiology and pathogenesis of NFLD.
References
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
Elizabeth M. Brunt,Christine G. Janney,Adrian M. Di Bisceglie,Brent A. Neuschwander-Tetri,Bruce R. Bacon +4 more
TL;DR: There are no systems for grading necroinflammatory activity or for staging fibrosis as exist for various other forms of chronic liver disease and this study proposes a grading and staging system that reflects the unique histological features of nonalcoholic steatohepatitis.
Journal ArticleDOI
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Christi A. Matteoni,Zobair M. Younossi,Terry Gramlich,Navdeep Boparai,Yao Chang Liu,Arthur J. McCullough +5 more
TL;DR: The outcome of cirrhosis and liver-related death is not uniform across the spectrum of nonalcoholic fatty liver, and poor outcomes are more frequent in patients in whom biopsies show ballooning degeneration and Mallory hyaline or fibrosis.
Journal Article
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
TL;DR: Findings in 20 patients with nonalcoholic steatohepatitis of unknown cause found the patients were moderately obese, and many had obesity-associated diseases, such as diabetes mellitus and cholelithiasis.
Journal ArticleDOI
Transaminase activity in human blood
TL;DR: To determine if transaminase activity could be demonstrated in human serum and blood cellular elements and, if so, to study any variations in activity of this enzyme in the blood of normal and diseased man.